Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

Martin Kropff; Stefan Goranov

$Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial$

Б 335

Детайли

Източник

Haematologica

Местоиздаване

Pavia

Година на издаване

2012

Пор.№

Страници

784-791

Класификационен индекс

УДК	Значение
616.71-018.46-006.448	Миелома

Том

Тематична група

Автори от МУ - Пловдив

Допълнителна информация

ISSN: 0390-6078
Системен №: 31579
Тематични рубрики: Хематология
Предметни рубрики: Миелом, Кръвотворна система - болести - терапия

Действия

APA Chicago / Turabian (16th edition) Harvard MLA (7th edition) Vancouver

Kropff, M., Goranov, S. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Pavia: 2012 784-791,.

Kropff, M., Goranov, S. (2012) Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial, Pavia: 784-791,.

Kropff, M., & Goranov, S. (2012). Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica, 97 (5), 784-791.

Kropff M, Goranov S. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012; 97(5): 784-791.